Safety and Effectiveness of Eylea Aflibercept Injection in Japanese Patients with Neovascular Glaucoma Observed in Routine Clinical Practice

What this Trial Is About

Researchers are conducting a prospective, observational, multi-center study to assess the safety and effectiveness of Eylea Aflibercept injection in patients diagnosed with Neovascular Glaucoma in Japan. This study focuses on patients for whom the decision to use Eylea has already been made by their doctors in routine clinical practice. The goal is to collect real-world data on how patients respond to this treatment over time. Participants receive Eylea through intravitreal injection as part of their usual care, with the treatment decision guided by the Japanese package insert. The study does not assign treatments but observes patients who have been prescribed Eylea. Patients are followed for up to six months from the start of their Eylea treatment or until they can no longer be followed, such as if they are lost to follow-up. During the study, data are collected at initial, follow-up, and final visits, aligned with routine medical appointments. Researchers assess safety by recording any adverse events and monitor effectiveness by measuring intraocular pressure, visual acuity changes, and improvements in anterior neovascularization. In total, 480 patients will be included, providing valuable information about Eyleas use in everyday clinical settings.

Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)